JP2015515992A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015515992A5 JP2015515992A5 JP2015510507A JP2015510507A JP2015515992A5 JP 2015515992 A5 JP2015515992 A5 JP 2015515992A5 JP 2015510507 A JP2015510507 A JP 2015510507A JP 2015510507 A JP2015510507 A JP 2015510507A JP 2015515992 A5 JP2015515992 A5 JP 2015515992A5
- Authority
- JP
- Japan
- Prior art keywords
- particle
- mol
- peg
- lipids
- agent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000002245 particle Substances 0.000 claims description 48
- 150000002632 lipids Chemical class 0.000 claims description 18
- 150000003904 phospholipids Chemical class 0.000 claims description 10
- 239000003795 chemical substances by application Substances 0.000 claims description 9
- 239000003814 drug Substances 0.000 claims description 9
- 229940124597 therapeutic agent Drugs 0.000 claims description 8
- 229940039227 diagnostic agent Drugs 0.000 claims description 6
- 239000000032 diagnostic agent Substances 0.000 claims description 6
- 239000002502 liposome Substances 0.000 claims description 6
- 239000002105 nanoparticle Substances 0.000 claims description 6
- 230000000069 prophylactic effect Effects 0.000 claims description 6
- 239000003381 stabilizer Substances 0.000 claims description 6
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 claims description 4
- RRHGJUQNOFWUDK-UHFFFAOYSA-N Isoprene Chemical compound CC(=C)C=C RRHGJUQNOFWUDK-UHFFFAOYSA-N 0.000 claims description 4
- 239000002246 antineoplastic agent Substances 0.000 claims description 4
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims description 4
- 230000005494 condensation Effects 0.000 claims description 4
- 238000009833 condensation Methods 0.000 claims description 4
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 claims description 4
- 229930182558 Sterol Natural products 0.000 claims description 2
- HNYOPLTXPVRDBG-UHFFFAOYSA-N barbituric acid Chemical group O=C1CC(=O)NC(=O)N1 HNYOPLTXPVRDBG-UHFFFAOYSA-N 0.000 claims description 2
- 235000012000 cholesterol Nutrition 0.000 claims description 2
- 235000014113 dietary fatty acids Nutrition 0.000 claims description 2
- 229960004679 doxorubicin Drugs 0.000 claims description 2
- 239000000194 fatty acid Substances 0.000 claims description 2
- 229930195729 fatty acid Natural products 0.000 claims description 2
- 150000004665 fatty acids Chemical class 0.000 claims description 2
- 150000002313 glycerolipids Chemical class 0.000 claims description 2
- 150000002327 glycerophospholipids Chemical class 0.000 claims description 2
- 239000012216 imaging agent Substances 0.000 claims description 2
- 229930001119 polyketide Natural products 0.000 claims description 2
- 125000000830 polyketide group Chemical group 0.000 claims description 2
- 150000003135 prenol lipids Chemical class 0.000 claims description 2
- 150000003313 saccharo lipids Chemical class 0.000 claims description 2
- 150000003408 sphingolipids Chemical class 0.000 claims description 2
- -1 sterol lipids Chemical class 0.000 claims description 2
- 235000003702 sterols Nutrition 0.000 claims description 2
- 230000001225 therapeutic effect Effects 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims 1
- 210000003097 mucus Anatomy 0.000 claims 1
- 238000000034 method Methods 0.000 description 2
- 229940079593 drug Drugs 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261642776P | 2012-05-04 | 2012-05-04 | |
| US61/642,776 | 2012-05-04 | ||
| PCT/US2013/039731 WO2013166498A1 (en) | 2012-05-04 | 2013-05-06 | Lipid-based drug carriers for rapid penetration through mucus linings |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017220782A Division JP2018039836A (ja) | 2012-05-04 | 2017-11-16 | 粘液内層を通過する迅速な透過のための脂質ベース薬物キャリア |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015515992A JP2015515992A (ja) | 2015-06-04 |
| JP2015515992A5 true JP2015515992A5 (enExample) | 2016-06-23 |
| JP6392209B2 JP6392209B2 (ja) | 2018-09-19 |
Family
ID=48428718
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015510507A Active JP6392209B2 (ja) | 2012-05-04 | 2013-05-06 | 粘液内層を通過する迅速な透過のための脂質ベース薬物キャリア |
| JP2017220782A Withdrawn JP2018039836A (ja) | 2012-05-04 | 2017-11-16 | 粘液内層を通過する迅速な透過のための脂質ベース薬物キャリア |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017220782A Withdrawn JP2018039836A (ja) | 2012-05-04 | 2017-11-16 | 粘液内層を通過する迅速な透過のための脂質ベース薬物キャリア |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US9889208B2 (enExample) |
| EP (1) | EP2849728A1 (enExample) |
| JP (2) | JP6392209B2 (enExample) |
| AU (1) | AU2013256008B2 (enExample) |
| CA (1) | CA2872519C (enExample) |
| HK (1) | HK1208377A1 (enExample) |
| WO (1) | WO2013166498A1 (enExample) |
Families Citing this family (72)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8957034B2 (en) * | 2004-01-28 | 2015-02-17 | Johns Hopkins University | Drugs and gene carrier particles that rapidly move through mucous barriers |
| EP2538929A4 (en) | 2010-02-25 | 2014-07-09 | Univ Johns Hopkins | DELAYED RELEASE OF THERAPIES IN A PART OF THE EYE |
| EP3578205A1 (en) | 2010-08-06 | 2019-12-11 | ModernaTX, Inc. | A pharmaceutical formulation comprising engineered nucleic acids and medical use thereof |
| US10307372B2 (en) | 2010-09-10 | 2019-06-04 | The Johns Hopkins University | Rapid diffusion of large polymeric nanoparticles in the mammalian brain |
| EP4108671B1 (en) | 2010-10-01 | 2024-11-20 | ModernaTX, Inc. | Modified nucleosides, nucleotides, and nucleic acids, and uses thereof |
| WO2012109363A2 (en) | 2011-02-08 | 2012-08-16 | The Johns Hopkins University | Mucus penetrating gene carriers |
| JP2014511687A (ja) | 2011-03-31 | 2014-05-19 | モデルナ セラピューティクス インコーポレイテッド | 工学操作された核酸の送達および製剤 |
| US9464124B2 (en) | 2011-09-12 | 2016-10-11 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
| PL3682905T3 (pl) | 2011-10-03 | 2022-04-04 | Modernatx, Inc. | Modyfikowane nukleozydy, nukleotydy i kwasy nukleinowe oraz ich zastosowania |
| PL2791160T3 (pl) | 2011-12-16 | 2022-06-20 | Modernatx, Inc. | Kompozycje zmodyfikowanego mrna |
| WO2013138346A1 (en) | 2012-03-16 | 2013-09-19 | The Johns Hopkins University | Non-linear multiblock copolymer-drug conjugates for the delivery of active agents |
| HK1206270A1 (en) | 2012-03-16 | 2016-01-08 | The Johns Hopkins University | Controlled release formulations for the delivery of hif-1 inhibitors |
| US9572897B2 (en) | 2012-04-02 | 2017-02-21 | Modernatx, Inc. | Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins |
| US9283287B2 (en) | 2012-04-02 | 2016-03-15 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of nuclear proteins |
| US10501512B2 (en) | 2012-04-02 | 2019-12-10 | Modernatx, Inc. | Modified polynucleotides |
| WO2013151665A2 (en) | 2012-04-02 | 2013-10-10 | modeRNA Therapeutics | Modified polynucleotides for the production of proteins associated with human disease |
| KR102310775B1 (ko) | 2012-05-03 | 2021-10-07 | 칼라 파마슈티컬스, 인크. | 개선된 점막 수송을 나타내는 제약 나노입자 |
| US10688041B2 (en) | 2012-05-03 | 2020-06-23 | Kala Pharmaceuticals, Inc. | Compositions and methods utilizing poly(vinyl alcohol) and/or other polymers that aid particle transport in mucus |
| US11596599B2 (en) | 2012-05-03 | 2023-03-07 | The Johns Hopkins University | Compositions and methods for ophthalmic and/or other applications |
| US9827191B2 (en) | 2012-05-03 | 2017-11-28 | The Johns Hopkins University | Compositions and methods for ophthalmic and/or other applications |
| CA2872519C (en) | 2012-05-04 | 2017-09-05 | The Johns Hopkins University | Lipid-based drug carriers for rapid penetration through mucus linings |
| RS63237B1 (sr) | 2012-11-26 | 2022-06-30 | Modernatx Inc | Terminalno modifikovana rnk |
| US10568975B2 (en) | 2013-02-05 | 2020-02-25 | The Johns Hopkins University | Nanoparticles for magnetic resonance imaging tracking and methods of making and using thereof |
| WO2014152211A1 (en) | 2013-03-14 | 2014-09-25 | Moderna Therapeutics, Inc. | Formulation and delivery of modified nucleoside, nucleotide, and nucleic acid compositions |
| US8980864B2 (en) | 2013-03-15 | 2015-03-17 | Moderna Therapeutics, Inc. | Compositions and methods of altering cholesterol levels |
| WO2015048744A2 (en) | 2013-09-30 | 2015-04-02 | Moderna Therapeutics, Inc. | Polynucleotides encoding immune modulating polypeptides |
| JP2016538829A (ja) | 2013-10-03 | 2016-12-15 | モデルナ セラピューティクス インコーポレイテッドＭｏｄｅｒｎａ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． | 低密度リポタンパク質受容体をコードするポリヌクレオチド |
| WO2015175545A1 (en) | 2014-05-12 | 2015-11-19 | The Johns Hopkins University | Highly stable biodegradable gene vector platforms for overcoming biological barriers |
| CN107278151A (zh) | 2014-12-15 | 2017-10-20 | 约翰霍普金斯大学 | 舒尼替尼制剂及其在治疗青光眼中的使用方法 |
| EP3250184B1 (en) | 2015-01-27 | 2024-12-18 | The Johns Hopkins University | Hypotonic hydrogel formulations for enhanced transport of active agents at mucosal surfaces |
| US20180139997A1 (en) * | 2015-06-15 | 2018-05-24 | Gexnano S.R.L. | Food supplement for use in a process of metabolic rebalancing |
| WO2017035408A1 (en) | 2015-08-26 | 2017-03-02 | Achillion Pharmaceuticals, Inc. | Compounds for treatment of immune and inflammatory disorders |
| AR106018A1 (es) | 2015-08-26 | 2017-12-06 | Achillion Pharmaceuticals Inc | Compuestos de arilo, heteroarilo y heterocíclicos para el tratamiento de trastornos médicos |
| CA2997286A1 (en) | 2015-09-14 | 2017-03-23 | Vgsk Technologies, Inc. | A sterically stabilized carrier for subcutaneous, sublingual and oral therapeutics, compositions and methods for treating a mammal |
| ES2910425T3 (es) | 2015-09-17 | 2022-05-12 | Modernatx Inc | Compuestos y composiciones para la administración intracelular de agentes terapéuticos |
| MX2018003462A (es) | 2015-09-22 | 2018-09-06 | Graybug Vision Inc | Compuestos y composiciones para el tratamiento de trastornos oculares. |
| JP2018533579A (ja) * | 2015-10-30 | 2018-11-15 | ザ・ジョンズ・ホプキンス・ユニバーシティー | 高分子量かつ密な被覆を有する粘液浸透粒子 |
| KR20180102069A (ko) | 2015-11-12 | 2018-09-14 | 그레이버그 비젼, 인크. | 요법을 위한 응집성 마이크로입자 |
| WO2017090047A1 (en) * | 2015-11-27 | 2017-06-01 | Technology Innovation Momentum Fund (Israel) Limited Partnership | Glucosamine and derivatives thereof in imaging |
| WO2017099823A1 (en) | 2015-12-10 | 2017-06-15 | Modernatx, Inc. | Compositions and methods for delivery of therapeutic agents |
| DK3394030T3 (da) | 2015-12-22 | 2022-03-28 | Modernatx Inc | Forbindelser og sammensætninger til intracellulær afgivelse af midler |
| WO2017136700A1 (en) | 2016-02-05 | 2017-08-10 | The Trustees Of The University Of Pennsylvania | Non-nutritive sweeteners and polyols as imaging agents |
| US10901058B2 (en) * | 2016-02-05 | 2021-01-26 | The Trustees Of The University Of Pennsylvania | Chemical exchange saturation transfer (CEST) imaging of lactate (LATEST) |
| CN109152361A (zh) * | 2016-03-09 | 2019-01-04 | 技术研究及发展基金有限公司 | 脂质体制剂及在农业中使用该脂质体制剂的方法 |
| EP3448389B1 (en) | 2016-06-27 | 2021-09-29 | Achillion Pharmaceuticals, Inc. | Quinazoline and indole compounds to treat medical disorders |
| US10842746B1 (en) * | 2016-08-25 | 2020-11-24 | Verily Life Sciences Llc | Bi-directionally crosslinked liposomes and method of making same |
| WO2018089540A1 (en) | 2016-11-08 | 2018-05-17 | Modernatx, Inc. | Stabilized formulations of lipid nanoparticles |
| PT3985002T (pt) | 2017-03-01 | 2025-08-29 | Achillion Pharmaceuticals Inc | Compostos farmacêuticos de arilo, heteroarilo e heterocíclicos para tratamento de distúrbios médicos |
| US11203569B2 (en) | 2017-03-15 | 2021-12-21 | Modernatx, Inc. | Crystal forms of amino lipids |
| ES3020935T3 (en) | 2017-03-15 | 2025-05-23 | Modernatx Inc | Lipid nanoparticle formulation |
| LT3596041T (lt) | 2017-03-15 | 2023-01-25 | Modernatx, Inc. | Terapinių medžiagų, skirtų intraląsteliniam tiekimui, junginys ir sudėtys |
| MX2019011242A (es) | 2017-03-23 | 2020-01-21 | Graybug Vision Inc | Farmacos y composiciones para el tratamiento de trastornos oculares. |
| MX2019013363A (es) | 2017-05-10 | 2020-01-13 | Graybug Vision Inc | Microparticulas de liberacion extendida y suspensiones de las mismas para terapia medica. |
| US12077501B2 (en) | 2017-06-14 | 2024-09-03 | Modernatx, Inc. | Compounds and compositions for intracellular delivery of agents |
| EP3638215A4 (en) | 2017-06-15 | 2021-03-24 | Modernatx, Inc. | RNA FORMULATIONS |
| MX2020002348A (es) | 2017-08-31 | 2020-10-08 | Modernatx Inc | Métodos de elaboración de nanopartículas lipídicas. |
| US20210069121A1 (en) | 2017-12-12 | 2021-03-11 | Lead Biotherapeutics Ltd | Solid lipid nanoparticle for intracellular release of active substances and method for production the same |
| US20230022157A1 (en) | 2018-08-20 | 2023-01-26 | Achillion Pharmaceuticals, Inc. | Pharmaceutical compounds for the treatment of complement factor d medical disorders |
| JP7443375B2 (ja) | 2018-09-06 | 2024-03-05 | アキリオン ファーマシューティカルズ， インコーポレーテッド | 医学的障害の治療のための大環状化合物 |
| EP3849532A4 (en) * | 2018-09-13 | 2022-06-08 | Taiwan Liposome Company, Ltd. | SUSTAINED-RELEASE PHARMACEUTICAL COMPOSITIONS COMPRISING A SEDATIVE MEDICINE AND THEIR USES |
| CN112996854B (zh) | 2018-09-19 | 2024-08-30 | 摩登纳特斯有限公司 | 高纯度peg脂质和其用途 |
| EP3853202A1 (en) | 2018-09-19 | 2021-07-28 | ModernaTX, Inc. | Compounds and compositions for intracellular delivery of therapeutic agents |
| MA53650A (fr) | 2018-09-19 | 2021-07-28 | Modernatx Inc | Lipides peg et leurs utilisations |
| EP3852728B1 (en) | 2018-09-20 | 2024-09-18 | ModernaTX, Inc. | Preparation of lipid nanoparticles and methods of administration thereof |
| EP3866773B1 (en) | 2018-10-16 | 2024-08-28 | Georgia State University Research Foundation, Inc. | Carbon monoxide prodrugs for the treatment of medical disorders |
| WO2020210805A1 (en) | 2019-04-11 | 2020-10-15 | The Johns Hopkins University | Nanoparticles for drug delivery to brain |
| BR112022004759A2 (pt) | 2019-09-19 | 2022-06-21 | Modernatx Inc | Composições e compostos lipídicos com cauda ramificada para entrega intracelular de agentes terapêuticos |
| EP4107166A4 (en) | 2020-02-20 | 2024-06-26 | Achillion Pharmaceuticals, Inc. | HETEROARYL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT FACTOR D-MEDIATED DISORDERS |
| JP7787164B2 (ja) | 2020-09-23 | 2025-12-16 | アキリオン ファーマシューティカルズ， インコーポレーテッド | 補体媒介性障害の治療のための医薬化合物 |
| US11058637B1 (en) * | 2020-11-25 | 2021-07-13 | King Abdulaziz University | Surface-modified emulsomes for intranasal delivery of drugs |
| US11524023B2 (en) | 2021-02-19 | 2022-12-13 | Modernatx, Inc. | Lipid nanoparticle compositions and methods of formulating the same |
| EP4333809A4 (en) * | 2021-05-05 | 2025-03-12 | VGSK Technologies, Inc. | Liposomal-encapsulated corticosteroids to inhibit SARS-CoV-2 replication and reduce pneumonia |
Family Cites Families (95)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2026989A (en) | 1931-08-12 | 1936-01-07 | T R C Corp | Method of building roads |
| US2005204A (en) | 1933-02-23 | 1935-06-18 | Ralph R Poynter | Lawn mower |
| US5034506A (en) | 1985-03-15 | 1991-07-23 | Anti-Gene Development Group | Uncharged morpholino-based polymers having achiral intersubunit linkages |
| US4997652A (en) | 1987-12-22 | 1991-03-05 | Visionex | Biodegradable ocular implants |
| US5013556A (en) | 1989-10-20 | 1991-05-07 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
| US5356633A (en) * | 1989-10-20 | 1994-10-18 | Liposome Technology, Inc. | Method of treatment of inflamed tissues |
| US5196522A (en) | 1990-11-01 | 1993-03-23 | Board Of Regents, The University Of Texas System | Anthracycline analogues bearing latent alkylating substituents |
| US5696298A (en) | 1991-03-19 | 1997-12-09 | Cytrx Corporation | Polyoxypropylene/polyoxyethylene copolymers with improved biological activity |
| CA2117588C (en) | 1992-02-28 | 1998-08-25 | Jeffrey A. Hubbell | Photopolymerizable biodegradable hydrogels as tissue contacting materials and controlled-release carriers |
| US5565215A (en) | 1993-07-23 | 1996-10-15 | Massachusettes Institute Of Technology | Biodegradable injectable particles for imaging |
| US5540930A (en) | 1993-10-25 | 1996-07-30 | Pharmos Corporation | Suspension of loteprednol etabonate for ear, eye, or nose treatment |
| US6007845A (en) | 1994-07-22 | 1999-12-28 | Massachusetts Institute Of Technology | Nanoparticles and microparticles of non-linear hydrophilic-hydrophobic multiblock copolymers |
| US5576311A (en) | 1994-11-30 | 1996-11-19 | Pharmos Corporation | Cyclodextrins as suspending agents for pharmaceutical suspensions |
| US5628981A (en) | 1994-12-30 | 1997-05-13 | Nano Systems L.L.C. | Formulations of oral gastrointestinal diagnostic x-ray contrast agents and oral gastrointestinal therapeutic agents |
| US5932462A (en) | 1995-01-10 | 1999-08-03 | Shearwater Polymers, Inc. | Multiarmed, monofunctional, polymer for coupling to molecules and surfaces |
| US6413539B1 (en) | 1996-10-31 | 2002-07-02 | Poly-Med, Inc. | Hydrogel-forming, self-solvating absorbable polyester copolymers, and methods for use thereof |
| DK0751144T3 (da) | 1995-06-27 | 2004-12-27 | Pharmachemie Bv | Nye antracyclin-pro-drugs, fremgangsmåde til fremstilling deraf samt antitumorsammensætninger og et komponentkit indeholdende disse pro-drugs |
| KR20000010834A (ko) | 1996-05-09 | 2000-02-25 | 미셀 지. 베르제롱 | Hiv 및 hsv를 포함하는 병원체 유도질병의 예방용 조성물 |
| US5869130A (en) | 1997-06-12 | 1999-02-09 | Mac Dermid, Incorporated | Process for improving the adhesion of polymeric materials to metal surfaces |
| US7052678B2 (en) | 1997-09-15 | 2006-05-30 | Massachusetts Institute Of Technology | Particles for inhalation having sustained release properties |
| US6270806B1 (en) | 1999-03-03 | 2001-08-07 | Elan Pharma International Limited | Use of peg-derivatized lipids as surface stabilizers for nanoparticulate compositions |
| EP1178837A2 (en) | 1999-04-21 | 2002-02-13 | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | Method for enhancing contrast produced by mri |
| US6287588B1 (en) | 1999-04-29 | 2001-09-11 | Macromed, Inc. | Agent delivering system comprised of microparticle and biodegradable gel with an improved releasing profile and methods of use thereof |
| EP1088853B1 (en) | 1999-10-01 | 2004-10-13 | Toda Kogyo Corporation | Mg-Al-based hydrotalcite-type particles, chlorine-containing resin stabilizer and process for producing the particles |
| US20030147944A1 (en) * | 1999-12-10 | 2003-08-07 | Mayer Lawrence D | Lipid carrier compositions with protected surface reactive functions |
| US6589549B2 (en) | 2000-04-27 | 2003-07-08 | Macromed, Incorporated | Bioactive agent delivering system comprised of microparticles within a biodegradable to improve release profiles |
| US6495164B1 (en) | 2000-05-25 | 2002-12-17 | Alkermes Controlled Therapeutics, Inc. I | Preparation of injectable suspensions having improved injectability |
| PE20020146A1 (es) | 2000-07-13 | 2002-03-31 | Upjohn Co | Formulacion oftalmica que comprende un inhibidor de ciclooxigenasa-2 (cox-2) |
| AU2000202A (en) | 2000-10-31 | 2002-05-15 | Pr Pharmaceuticals Inc | Methods and compositions for enhanced delivery of bioactive molecules |
| GB0122318D0 (en) | 2001-09-14 | 2001-11-07 | Novartis Ag | Organic compounds |
| US7381426B2 (en) * | 2002-01-24 | 2008-06-03 | Southwest Research Institute | Targeted delivery of bioactive factors to the systemic skeleton |
| CA2491164C (en) * | 2002-06-28 | 2012-05-08 | Cory Giesbrecht | Method and apparatus for producing liposomes |
| JP4490291B2 (ja) | 2002-12-30 | 2010-06-23 | ネクター セラピューティクス アラバマ，コーポレイション | 薬物送達媒体としてのマルチアーム（ｍｕｌｔｉ−ａｒｍ）ポリペプチド−ポリ（エチレングリコール）ブロックコポリマー |
| US20050009910A1 (en) | 2003-07-10 | 2005-01-13 | Allergan, Inc. | Delivery of an active drug to the posterior part of the eye via subconjunctival or periocular delivery of a prodrug |
| CN1867580B (zh) * | 2003-09-03 | 2010-09-29 | 协和发酵麒麟株式会社 | 被甘油衍生物修饰的化合物 |
| GB0328630D0 (en) | 2003-12-10 | 2004-01-14 | Medpharm Ltd | Metered dose inhalation preparations |
| EP1701704A2 (en) | 2003-12-31 | 2006-09-20 | Pfizer Products Inc. | Solid compositions of low-solubility drugs and poloxamers |
| US8957034B2 (en) | 2004-01-28 | 2015-02-17 | Johns Hopkins University | Drugs and gene carrier particles that rapidly move through mucous barriers |
| CA2555335A1 (en) | 2004-02-05 | 2005-08-25 | Intradigm Corporation | Rnai therapeutics for treatment of eye neovascularization diseases |
| ES2246694B1 (es) | 2004-04-29 | 2007-05-01 | Instituto Cientifico Y Tecnologico De Navarra, S.A. | Nanoparticulas pegiladas. |
| WO2005107708A1 (en) | 2004-04-30 | 2005-11-17 | Allergan, Inc. | Biodegradable intravitreal tyrosine kinase inhibitors implants |
| US20050244469A1 (en) | 2004-04-30 | 2005-11-03 | Allergan, Inc. | Extended therapeutic effect ocular implant treatments |
| US7771742B2 (en) | 2004-04-30 | 2010-08-10 | Allergan, Inc. | Sustained release intraocular implants containing tyrosine kinase inhibitors and related methods |
| CA2590098C (en) | 2004-12-10 | 2015-03-31 | Justin Hanes | Functionalized poly (ether-anhydride) block copolymers |
| WO2006116107A2 (en) * | 2005-04-22 | 2006-11-02 | Alza Corporation | Immunoliposome composition for targeting to a her2 cell receptor |
| JP2006335745A (ja) * | 2005-06-06 | 2006-12-14 | Fujifilm Holdings Corp | リポソームを含むｍｒｉ造影剤 |
| WO2007016380A2 (en) | 2005-07-28 | 2007-02-08 | (Osi) Eyetech, Inc. | Cyclitol linker polymer conjugate |
| US20070071756A1 (en) | 2005-09-26 | 2007-03-29 | Peyman Gholam A | Delivery of an agent to ameliorate inflammation |
| US20070093461A1 (en) | 2005-10-26 | 2007-04-26 | Bausch & Lomb Incorporated | Effect of Loteprednol etabonate on vascular dysfunction |
| US8658608B2 (en) | 2005-11-23 | 2014-02-25 | Yale University | Modified triple-helix forming oligonucleotides for targeted mutagenesis |
| JP2009521493A (ja) | 2005-12-23 | 2009-06-04 | アルコン，インコーポレイテッド | 眼への受容体チロシンキナーゼ阻害（ＲＴＫｉ）化合物の送達のための医薬製剤 |
| US8663674B2 (en) | 2006-01-13 | 2014-03-04 | Surmodics, Inc. | Microparticle containing matrices for drug delivery |
| US20070231360A1 (en) | 2006-03-28 | 2007-10-04 | Minu, L.L.C. | Neural conduit agent dissemination |
| US20080166411A1 (en) | 2006-04-10 | 2008-07-10 | Pfizer Inc | Injectable Depot Formulations And Methods For Providing Sustained Release Of Poorly Soluble Drugs Comprising Nanoparticles |
| US20070249536A1 (en) | 2006-04-25 | 2007-10-25 | Ma Peter X | Three-component polyanhydride copolymers and a method of forming the same |
| US8858989B2 (en) * | 2006-05-18 | 2014-10-14 | Biolitec Pharma Marketing Ltd | Gel-formulations of hydrophobic photosensitizers for mucosal applications |
| JP2008053276A (ja) | 2006-08-22 | 2008-03-06 | Nec Electronics Corp | 半導体装置の製造方法 |
| AU2007292902B8 (en) | 2006-09-08 | 2013-09-05 | Johns Hopkins University | Compositions and methods for enhancing transport through mucus |
| US8394488B2 (en) | 2006-10-06 | 2013-03-12 | Cordis Corporation | Bioabsorbable device having composite structure for accelerating degradation |
| TWI409081B (zh) | 2006-11-09 | 2013-09-21 | Alcon Res Ltd | 用於藥物輸送之水不溶性聚合物基質 |
| US20080213352A1 (en) * | 2007-03-02 | 2008-09-04 | Luna Innovations Incorporated | Liposome carriers for in vivo delivery of fullerenes |
| CN101820917B (zh) | 2007-10-08 | 2013-01-02 | 佛维雅制药股份有限公司 | 水性眼科配制剂 |
| JP2009096749A (ja) * | 2007-10-16 | 2009-05-07 | Konica Minolta Holdings Inc | コレステロール誘導体、リポソーム及びｘ線用造影剤 |
| US20090203709A1 (en) | 2008-02-07 | 2009-08-13 | Abbott Laboratories | Pharmaceutical Dosage Form For Oral Administration Of Tyrosine Kinase Inhibitor |
| TW201019963A (en) * | 2008-09-10 | 2010-06-01 | Abbott Lab | Polyethylene glycol lipid conjugates and uses thereof |
| SG195531A1 (en) | 2008-10-10 | 2013-12-30 | Bionic Ear Inst | Biodegradable polymer - bioactive moiety conjugates |
| WO2010091187A2 (en) | 2009-02-04 | 2010-08-12 | The Brigham And Women's Hospital, Inc. | Polymeric nanoparticles with enhanced drug-loading and methods of use thereof |
| BRPI1012302A2 (pt) | 2009-03-03 | 2015-09-22 | Alcon Res Ltd | composição farmacêutica para a liberação de compostos de inibição de tirosina quinase receptora (rtki) para o olho |
| US10952965B2 (en) | 2009-05-15 | 2021-03-23 | Baxter International Inc. | Compositions and methods for drug delivery |
| WO2010143969A2 (en) * | 2009-06-08 | 2010-12-16 | Epitarget As | Acoustically sensitive drug delivery particles comprising non-lamellar forming phosphatidylethanolamine |
| EP2335686A1 (en) | 2009-12-21 | 2011-06-22 | LEK Pharmaceuticals d.d. | An aqueous intravenous nanosuspension with reduced adverse effects |
| EP2538929A4 (en) | 2010-02-25 | 2014-07-09 | Univ Johns Hopkins | DELAYED RELEASE OF THERAPIES IN A PART OF THE EYE |
| US20130071349A1 (en) | 2010-03-02 | 2013-03-21 | Allergan, Inc. | Biodegradable polymers for lowering intraocular pressure |
| US20110262406A1 (en) | 2010-04-21 | 2011-10-27 | Yale University | Compositions and methods for targeted inactivation of hiv cell surface receptors |
| EP2407157A1 (en) * | 2010-07-13 | 2012-01-18 | Koninklijke Philips Electronics N.V. | Lipid bilayer carrier for drugs or imaging agents |
| US10307372B2 (en) | 2010-09-10 | 2019-06-04 | The Johns Hopkins University | Rapid diffusion of large polymeric nanoparticles in the mammalian brain |
| CA3054532C (en) | 2010-11-05 | 2022-07-12 | The Johns Hopkins University | Compositions and methods relating to reduced mucoadhesion |
| WO2012109363A2 (en) | 2011-02-08 | 2012-08-16 | The Johns Hopkins University | Mucus penetrating gene carriers |
| CN102379850B (zh) * | 2011-11-04 | 2013-08-28 | 北京泰德制药股份有限公司 | 一种穿越人体粘液屏障的靶向给药脂质体 |
| CN104105507B (zh) | 2011-12-14 | 2020-03-24 | 约翰霍普金斯大学 | 增强粘膜渗透或减少炎症的纳米粒子 |
| US20130217657A1 (en) | 2011-12-21 | 2013-08-22 | Insite Vision Incorporated | Combination anti-inflammatory ophthalmic compositions |
| AU2013209452B2 (en) | 2012-01-19 | 2015-11-05 | The Johns Hopkins University | Nanoparticle formulations with enhanced mucosal penetration |
| EP2819652A1 (en) * | 2012-02-27 | 2015-01-07 | Epitarget As | Use of a particulate immunomodulator in cancer therapy |
| WO2013138346A1 (en) | 2012-03-16 | 2013-09-19 | The Johns Hopkins University | Non-linear multiblock copolymer-drug conjugates for the delivery of active agents |
| HK1206270A1 (en) | 2012-03-16 | 2016-01-08 | The Johns Hopkins University | Controlled release formulations for the delivery of hif-1 inhibitors |
| US20140107025A1 (en) | 2012-04-16 | 2014-04-17 | Jade Therapeutics, Llc | Ocular drug delivery system |
| NZ741873A (en) | 2012-05-03 | 2019-04-26 | Kala Pharmaceuticals Inc | Pharmaceutical nanoparticles showing improved mucosal transport |
| KR102310775B1 (ko) | 2012-05-03 | 2021-10-07 | 칼라 파마슈티컬스, 인크. | 개선된 점막 수송을 나타내는 제약 나노입자 |
| US10688041B2 (en) | 2012-05-03 | 2020-06-23 | Kala Pharmaceuticals, Inc. | Compositions and methods utilizing poly(vinyl alcohol) and/or other polymers that aid particle transport in mucus |
| US9827191B2 (en) | 2012-05-03 | 2017-11-28 | The Johns Hopkins University | Compositions and methods for ophthalmic and/or other applications |
| CA2872519C (en) | 2012-05-04 | 2017-09-05 | The Johns Hopkins University | Lipid-based drug carriers for rapid penetration through mucus linings |
| HK1211468A1 (en) | 2012-09-17 | 2016-05-27 | Pfizer Inc. | Therapeutic nanoparticles comprising a therapeutic agent and methods of making and using same |
| KR20150090038A (ko) | 2012-09-20 | 2015-08-05 | 아키나, 인크. | 충전재를 함유한 생분해성 미세캡슐 |
| US9968603B2 (en) | 2013-03-14 | 2018-05-15 | Forsight Vision4, Inc. | Systems for sustained intraocular delivery of low solubility compounds from a port delivery system implant |
| WO2014165308A2 (en) | 2013-04-01 | 2014-10-09 | Allergan, Inc. | Microsphere drug delivery system for sustained intraocular release |
-
2013
- 2013-05-06 CA CA2872519A patent/CA2872519C/en active Active
- 2013-05-06 HK HK15109178.8A patent/HK1208377A1/xx unknown
- 2013-05-06 JP JP2015510507A patent/JP6392209B2/ja active Active
- 2013-05-06 AU AU2013256008A patent/AU2013256008B2/en active Active
- 2013-05-06 US US14/397,828 patent/US9889208B2/en active Active
- 2013-05-06 EP EP13722265.9A patent/EP2849728A1/en not_active Withdrawn
- 2013-05-06 WO PCT/US2013/039731 patent/WO2013166498A1/en not_active Ceased
-
2017
- 2017-11-16 JP JP2017220782A patent/JP2018039836A/ja not_active Withdrawn
-
2018
- 2018-02-06 US US15/890,156 patent/US10556017B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015515992A5 (enExample) | ||
| US12409227B2 (en) | Cochleates made with soy phosphatidylserine | |
| JP2014532665A5 (enExample) | ||
| JP2018184470A5 (enExample) | ||
| JP2017515913A5 (enExample) | ||
| JP2015519383A5 (enExample) | ||
| WO2012021107A3 (en) | A liposomal formulation for ocular drug delivery | |
| EP3116479A1 (en) | Liposomal compositions for mucosal delivery | |
| WO2017019636A1 (en) | Compositions and methods for the treatment of sarcoidosis | |
| FI3954360T3 (fi) | Hiilihydraattien lääkevalmiste terapeuttiseen käyttöön | |
| ES2749192T3 (es) | Silibina para el tratamiento de las alteraciones oxidativas metabólicas en pacientes con esteatohepatitis no alcohólica (EHNA) | |
| CN112272555A (zh) | 用于治疗增殖性障碍的给药方案 | |
| CN110248666A (zh) | 甲钴胺素的鼻内用组合物 | |
| Terakosolphan et al. | Solubility of fluticasone propionate and beclomethasone dipropionate in simulated lung lining fluids | |
| JP5963973B2 (ja) | 最小閾値を超えるアルブミン、コレステロール及びｈｄｌの各レベルを有する患者の敗血症の治療方法 | |
| HK40044373A (en) | Dosing regimens for treatment of proliferative disorders | |
| NZ732995A (en) | Pharmaceutical combination comprising a biocompatible nanoparticle and a pharmaceutical compound, preparation and uses thereof | |
| HK1211181B (en) | Cochleates made with soy phosphatidylserine | |
| NZ732995B2 (en) | Pharmaceutical combination comprising a biocompatible nanoparticle and a pharmaceutical compound, preparation and uses thereof |